From 380c18b4b662dcfed7b41ed72c9bc15cafbd3dcc Mon Sep 17 00:00:00 2001
From: HouTeng Chan <ht-chen21@mails.tsinghua.edu.cn>
Date: Mon, 30 Sep 2024 11:07:09 +0000
Subject: [PATCH] Update file human-practices.html
---
wiki/pages/human-practices.html | 35 +++++++++++++++++++++++++++++----
1 file changed, 31 insertions(+), 4 deletions(-)
diff --git a/wiki/pages/human-practices.html b/wiki/pages/human-practices.html
index d5f3e215..24ec3c43 100644
--- a/wiki/pages/human-practices.html
+++ b/wiki/pages/human-practices.html
@@ -551,10 +551,6 @@
</div>
</div>
-
-
-
-
<div class="row mt-4">
<div class="col-lg-12">
<h2 id="Society/Politics">
@@ -563,6 +559,37 @@
</div>
</div>
+ <div class="row mt-4">
+ <div class="col-lg-12">
+ <div class="expert-card" onclick="toggleContent(this)">
+ <div class="row">
+ <div class="col-md-3">
+ <img src="https://static.igem.wiki/teams/5187/wiki-hp-fig/li-ji.jpg" alt="yhf" class="expert-image">
+ </div>
+ <div class="col-md-9 expert-details">
+ <span class="expert-name">Li Ji</span>
+ <span class="expert-role">Expert</span>
+ <p class="expert-takeaway">
+ <strong>Takeaway</strong><br>
+ A thorough understanding of clinical condition is vital for our engineering design. We acquired expert advice from the lecture of Dr Li Ji, a gastroenterologist in Peking Union Hospital. He comprehensively explained the classification, epidemiology, diagnosis, etiology and treatment of IBD. We focused on the current treatment, including their strengths and weaknesses, and analyzed the unique advantages of our cure.
+ </p>
+ <div class="expert-content">
+ <p><strong>Who</strong><br>
+ Li Ji, Deputy Director, Chief Physician and Master Supervisor of the Department of Gastroenterology, Peking Union Hospital. He specializes in the diagnosis and treatment of difficult and rare intestinal diseases such as inflammatory bowel disease, Cronkhite-Canada syndrome, hereditary gastrointestinal malformation polyposis, eosinophilic gastroenteritis, coeliac disease and autoimmune bowel disease.
+ <p><strong>Why</strong><br>
+ Before designing practical therapies for IBD, it is essential that we have a comprehensive understanding of the disease, encompassing both its pathophysiological mechanisms and the current status of clinical diagnosis and treatment. Information found online can be overwhelming, whereas reports from clinicians will be concise, comprehensive, and directly relevant to clinical practice. Therefore, we attended an authoritative report on IBD by Dr. Li from Peking Union Hospital.</p>
+ <p>Dr. Li began by explaining the definition and classification of IBD. Inflammatory Bowel Disease (IBD) is a group of non-specific inflammatory conditions of the intestines that are chronic and recurrent, and it can be categorized into Crohn's disease, ulcerative colitis, and indeterminate types. In China, there is a noticeable upward trend in the hospitalization rates for IBD. The pathogenesis of IBD is not yet fully understood but is influenced by genetic predisposition, environmental factors (such as infection, sanitation, and gut microbiota), and the body's immune response (such as disorders of the innate immune system). There is no gold standard for the diagnosis of IBD; however, it should be considered when symptoms such as mucusy blood-stained stools and recurrent abdominal pain are present. In terms of medication, the principle is to consider the course of the disease, the patient's age, previous treatment responses, and extraintestinal manifestations, among other factors, with the aim of achieving sustained mucosal healing without the use of steroids. Medications for treating IBD are classified into four major categories: aminosalicylates, corticosteroids, immunosuppressants, biologics and small molecule drugs, with biologics and small molecule drugs being more expensive and less accessible. At Peking Union Hospital, the treatment of IBD involves multiple departments, including outpatient services, endoscopy, and fecal microbiota transplantation, as well as the biologics.</p>
+ <p>Dr. Li's introduction provided us with an invaluable overview. We had a comprehensive and reliable understanding of IBD, which allowed us to design our project more targetedly. Moreover, the increasing trend of IBD patients in China, the challenges of recurrent and refractory IBD, and the high cost of biologic medications for IBD all underscored the necessity of our project.</p>
+ </div>
+ </div>
+ </div>
+ </div>
+ </div>
+ </div>
+
+
+
+
<div class="row mt-4">
<div class="col-lg-12">
<h2 id="Imaginary">
--
GitLab